Linda Bosch

After my training at the Netherlands Cancer Institute, I have been working as a clinical molecular biologist in pathology (KMBP) since 2022. As coordinator of molecular tumor diagnostics, I am responsible for organizing and coordinating the daily process within our team. Together with my colleagues, I am involved in the molecular analysis of tumors. We determine the genetic characteristics, such as DNA mutations, that are essential for making the correct diagnosis and for choosing the most appropriate treatment.

Molecular diagnostics is a dynamic and innovative field, in which we continuously monitor and apply new developments. The collaboration with medical specialists is essential to offer patients the best possible treatment plan. In addition to my diagnostic work, I am involved in clinical studies, in which we test new biomarkers and molecular techniques for future application in routine molecular diagnostics.

What makes the Netherlands Cancer Institute special for me is the specialized patient care that is constantly improved by the innovation of molecular techniques and advances in clinical studies. This allows us to provide the best care to our patients together, with the most up-to-date and innovative treatment methods.

More information about molecular tumor diagnostics can be found on our website.